Form 4: Bolt Biotherapeutics Director Reprices Stock Options

Bolt Biotherapeutics director Nicole Onetto exchanged multiple underwater stock options for new options with a significantly lower exercise price of $5.44.

Summary

• Nicole Onetto, a Director at Bolt Biotherapeutics, Inc. (BOLT), engaged in a series of derivative security transactions on December 12, 2025.
• She disposed of seven tranches of existing Director Stock Options with original exercise prices ranging from $6.40 to $83.80.
• Concurrently, she acquired new Director Stock Options for the same number of underlying common shares, but all with a significantly lower exercise price of $5.44.
• The total number of underlying common shares involved in these repriced options is 7,811.
• The purpose of these transactions was to cancel existing options granted between December 2021 and May 2025, which likely had exercise prices above the current market price, and replace them with new options at a more favorable exercise price.
• One new option tranche for 1,100 shares, originally granted on May 27, 2025, will vest on the earlier of May 27, 2026, or the day immediately prior to the next annual meeting of stockholders, subject to continuous service, with full vesting upon a change in control.

Sentiment

Score: 3

Explanation: The repricing of options, while beneficial for the director's incentive, is generally a negative signal for shareholders as it indicates significant past stock underperformance and can raise corporate governance concerns.

Positives

• The repricing of options restores incentive value for Director Nicole Onetto, potentially aligning her interests with future stock price appreciation from the new, lower strike price.

Negatives

• The repricing of options suggests that the company's stock price has significantly underperformed, rendering previous grants 'underwater' with original exercise prices as high as $83.80.
• This action can be viewed negatively by shareholders as it effectively re-grants options at a lower price, potentially diluting shareholder value and rewarding directors despite poor stock performance.

Risks

• Frequent or significant option repricing can raise corporate governance concerns and may negatively impact investor confidence regarding management accountability for stock performance.
• The necessity for repricing highlights past stock underperformance, which could continue to be a challenge for the company.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the vesting schedule of one option tranche and the expiration dates of the new options. The repricing itself implies a management belief in future stock price recovery to make the new options valuable.

Management Comments

• The reporting person agreed to cancellation of an option granted on [specific date], in exchange for a new option having a lower exercise price.

Industry Context

Option repricing is a common practice in industries, particularly biotechnology, where stock prices can be highly volatile due to factors like clinical trial results, regulatory approvals, or funding rounds. When a company's stock price falls significantly, options granted at higher prices become 'underwater,' losing their incentive value. Repricing aims to restore this incentive, but it can be controversial.

Comparison to Industry Standards

• Option repricing is generally viewed as a last resort by many institutional investors and proxy advisory firms (e.g., ISS, Glass Lewis) as it can signal poor past performance and dilute shareholder value.
• While not uncommon in volatile sectors like biotech, best practices often involve shareholder approval for such repricings or linking new grants to future performance metrics rather than simply lowering the strike price.
• Companies like Bolt Biotherapeutics, operating in the drug development space, often face significant stock price fluctuations, making option repricing a tool used to retain and motivate key personnel when stock performance lags.

Corporate Governance

Related Party Transactions

• Director Nicole Onetto, a related party, engaged in the repricing of her stock options, exchanging existing options for new ones with a lower exercise price.

Stakeholder Impact

• Shareholders: Potential negative impact due to perceived dilution and rewarding management/directors despite poor stock performance. May raise concerns about corporate governance and accountability.
• Director (Nicole Onetto): Positive impact as her stock options are now 'in-the-money' or closer to it, restoring their incentive value and potential for future gains.
• Employees: Could potentially set a precedent for future option repricings for other employees, which might be seen as positive for morale if their options are also underwater, but negative if they perceive it as unfair to shareholders.

Next Steps

• The 1,100 new stock options granted on May 27, 2025, will vest on the earlier of May 27, 2026, or the day immediately prior to the next annual meeting of stockholders.
• Full vesting of these 1,100 options will occur upon a change in control of the Issuer.

Key Dates

Recommendation

While the repricing of options indicates significant past stock underperformance, it also serves to re-incentivize a key director. For a seasoned investor, this event alone doesn't necessarily warrant a 'sell' unless there are broader fundamental issues. It might suggest a 'hold' to observe if the renewed incentive translates into improved performance or if the company's underlying business fundamentals can support a recovery, making the new options valuable. However, it certainly doesn't signal a 'buy' given the historical stock price weakness implied by the repricing.

Keywords

Bolt Biotherapeutics, BOLT, SEC Form 4, Stock Options, Option Repricing, Director Compensation, Insider Transaction, Equity Compensation, Corporate Governance